Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia

Drugs and Aging

Volumn 21, Issue 15, 2004, Pages 1025-1032

  Lipka, Leslie ^a   Sager, Philip ^a   Strony, John ^a   Yang, Bo ^a   Suresh, Ramachandran ^a   Veltri, Enrico ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; AGING; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW TOXICITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GERIATRIC PATIENT; HEPATOBILIARY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PAIN; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AGING; ALANINE TRANSAMINASE; ANTICHOLESTEREMIC AGENTS; ASPARTATE AMINOTRANSFERASES; AZETIDINES; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED;

EID: 11344285421     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421150-00005     Document Type: Article

References (25)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
2. American Heart Association. Heart disease and stroke statistics: 2004 update. Dallas (TX): American Heart Association, 2004
3. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986; 111: 383-90
4. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
6. Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 2002; 89: 67-9
7. Mungall MM, Gaw A, Shepherd J. Statin therapy in the elderly: does it make good clinical and economic sense? Drugs Aging 2003; 20: 263-75
8. Lemaitre RN, Furberg CD, Newman AB, et al. Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study. Arch Intern Med 1998; 158: 1761-8
9. Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocarcardial Infarction 3. Circulation 2001; 103: 38-44
10. Eaton CB, Lapane KL, Murphy JB, et al. Effect of statin (HMG-Co-A-Reductase Inhibitor) use on 1-year mortality and hospitalization rates in older patients with cardiovascular disease living in nursing homes. J Am Geriatr Soc 2002; 50: 1389-95
11. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511
12. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553-64
13. Van Heek M, Parley C, Compton DS, et al. Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats. Br J Pharmacol 2003; 138: 1459-64
14. Van Heek M, Compton DS, Davis HR. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 2001; 415: 79-84
15. Van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997; 283: 157-63
16. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24: 729-41
17. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003; 91: 418-24
18. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125-34
19. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-15
20. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003; 24: 717-28
21. Arias E, Andersen RN, Kung HC, et al. Death; final data for 2001. National vital statistics reports. Hyattsville (MD): National Center for Health Statistics, 2003
22. Harris WS, Held SJ, Dujovne CA. Comparison of two scoring systems used to monitor diets in outpatient clinical trials. J Cardiovasc Risk 1995; 2: 359-65
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
24. NCEP expert panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-23
25. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9